Coronary arterial morphology 10 years after “Endarterectomy”
نویسندگان
چکیده
منابع مشابه
Arterial hypertension developing 10 years after radiotherapy for Wilms's tumour.
Three patients developed arterial hypertension more than 10 years after receiving irradiation for Wilm's tumour. Scattered radiation appeared to have caused changes in the remaining kidney which were not severe enough to inhibit compensatory hypertrophy but which produced a rise in blood pressure at a later date. Since arterial hypertension appears to be a delayed complication of radiotherapy w...
متن کاملImpact of restenosis 10 years after coronary angioplasty.
AIMS The aim of the study was to compare the 10-year follow-up results of patients with or without restenosis following single-vessel percutaneous transluminal coronary angioplasty (PTCA). METHODS AND RESULTS A total of 313 patients with successful PTCA (> or = 20% reduction in luminal diameter narrowing without acute complications) and a control angiography 6 months after PTCA were included ...
متن کاملRegional anaesthesia for carotid endarterectomy: an audit over 10 years.
BACKGROUND The aim of this retrospective study was to compare the failure rates and the frequency of anaesthesia-related complications of two different methods of regional anaesthesia used for carotid endarterectomy--cervical epidural (CE) anaesthesia and cervical plexus block (CPB). METHODS The study included 1828 carotid endarterectomies performed in 1455 patients between 1996 and 2006. A c...
متن کاملPulmonary arterial compliance and exercise capacity after pulmonary endarterectomy.
Patients with chronic thromboembolic pulmonary hypertension (CTEPH), despite successful pulmonary endarterectomy (PEA), can continue to suffer from a limitation in exercise capacity. The objective of this study was to assess whether pulmonary arterial compliance is a predictor of exercise capacity after PEA. Right heart haemodynamics, treadmill incremental exercise test, spirometry, carbon mono...
متن کاملPegvisomant: Balance after 10 years.
El pegvisomant (PEG) fue aprobado por la Agencia Europea del Medicamento en noviembre del 2002 para pacientes con acromegalia persistente tras la cirugía y no controlados con análogos de la somatostatina (SSA). En España se comercializó en el año 2004, por lo que transcurridos más de 10 años parece adecuado reflexionar sobre nuestra experiencia con su uso, revisar los últimos datos sobre su efi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cardiology
سال: 1990
ISSN: 0160-9289,1932-8737
DOI: 10.1002/clc.4960130315